MeSH term
Frequency | Condition_Probility | Adolescent | 2 | 0.0 |
Adult | 7 | 0.0 |
Aged | 3 | 0.0 |
Amino Acid Sequence | 18 | 0.0 |
Amino Acid Substitution | 2 | 0.0 |
*Bacterial Proteins | 38 | 19.0 |
*Carrier Proteins | 4 | 0.0 |
Child | 10 | 0.0 |
Electrophoresis, Gel, Pulsed-Field | 6 | 2.0 |
Hexosyltransferases/chemistry/*genetics | 2 | 100.0 |
Humans | 101 | 0.0 |
Microbial Sensitivity Tests | 20 | 8.0 |
Middle Aged | 6 | 0.0 |
Molecular Sequence Data | 30 | 0.0 |
Multienzyme Complexes/chemistry/*genetics | 2 | 25.0 |
*Muramoylpentapeptide Carboxypeptidase | 4 | 80.0 |
Mutation | 9 | 0.0 |
Penicillin-Binding Proteins | 44 | 88.0 |
Peptidyl Transferases/chemistry/*genetics | 2 | 100.0 |
Phylogeny | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 61 | 0.0 |
Carrier Proteins/*analysis/genetics | 3 | 12.0 |
Comparative Study | 11 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 7 | 0.0 |
*Hexosyltransferases | 40 | 78.0 |
Muramoylpentapeptide Carboxypeptidase/*analysis/genetics | 3 | 100.0 |
*Penicillin Resistance | 12 | 75.0 |
Penicillins/*pharmacology | 7 | 46.0 |
*Peptidyl Transferases | 40 | 88.0 |
Aged, 80 and over | 2 | 0.0 |
*Amino Acid Substitution | 2 | 2.0 |
*Aminoacyltransferases | 7 | 87.0 |
Binding Sites/genetics | 2 | 0.0 |
Child, Preschool | 8 | 0.0 |
Infant | 8 | 0.0 |
Penicillin Resistance | 5 | 38.0 |
Penicillins/pharmacology | 7 | 63.0 |
Pneumococcal Infections/microbiology | 3 | 60.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Streptococcus pneumoniae/*drug effects/genetics/metabolism | 2 | 100.0 |
Anti-Bacterial Agents/pharmacology | 2 | 1.0 |
Microbial Sensitivity Tests/*methods | 2 | 22.0 |
beta-Lactamases/*metabolism | 2 | 66.0 |
beta-Lactams | 3 | 37.0 |
Ampicillin Resistance/genetics | 2 | 100.0 |
Binding, Competitive | 3 | 0.0 |
DNA, Bacterial/genetics | 4 | 5.0 |
In Vitro | 3 | 0.0 |
Molecular Weight | 4 | 0.0 |
Acute Disease | 6 | 0.0 |
Carrier Proteins/*genetics | 7 | 0.0 |
Female | 11 | 0.0 |
Male | 12 | 0.0 |
Muramoylpentapeptide Carboxypeptidase/*genetics | 7 | 100.0 |
Nasopharynx/*microbiology | 3 | 50.0 |
Otitis Media/*microbiology | 2 | 66.0 |
Penicillin Resistance/genetics | 6 | 66.0 |
Polymerase Chain Reaction | 12 | 0.0 |
Cephalosporins/*pharmacology | 2 | 50.0 |
Drug Resistance, Multiple/*physiology | 2 | 8.0 |
Staphylococcus aureus/*drug effects | 2 | 28.0 |
Streptococcus pneumoniae/drug effects | 2 | 66.0 |
Animals | 22 | 0.0 |
Base Sequence | 20 | 0.0 |
Carrier Proteins/*biosynthesis/genetics | 2 | 3.0 |
Cloning, Molecular | 8 | 0.0 |
Gene Expression | 4 | 0.0 |
Genes, Bacterial | 5 | 4.0 |
Muramoylpentapeptide Carboxypeptidase/*biosynthesis/genetics | 2 | 100.0 |
Penicillin Resistance/genetics/*physiology | 2 | 100.0 |
Binding Sites | 5 | 0.0 |
Immunohistochemistry | 3 | 0.0 |
Megakaryocytes/*metabolism | 2 | 6.0 |
Mice | 10 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 22 | 0.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Protein Binding | 5 | 0.0 |
Variation (Genetics) | 4 | 0.0 |
Cell Line | 8 | 0.0 |
Anti-Bacterial Agents/*pharmacology | 5 | 3.0 |
Time Factors | 2 | 0.0 |
Models, Biological | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Carrier Proteins/genetics | 7 | 1.0 |
Genotype | 7 | 0.0 |
Muramoylpentapeptide Carboxypeptidase/genetics | 7 | 100.0 |
Penicillins/therapeutic use | 2 | 15.0 |
Pneumococcal Infections/*epidemiology | 2 | 100.0 |
Polymorphism, Restriction Fragment Length | 6 | 0.0 |
Serotyping | 8 | 3.0 |
Infant, Newborn | 3 | 0.0 |
Multigene Family | 2 | 0.0 |
Streptococcus pneumoniae/classification/drug effects/*isolation & | 2 | 100.0 |
Amoxicillin/*pharmacology | 2 | 100.0 |
Carrier Proteins/metabolism | 4 | 0.0 |
Muramoylpentapeptide Carboxypeptidase/metabolism | 4 | 100.0 |
beta-Lactamases/metabolism | 2 | 50.0 |
Blood Platelets/*physiology | 3 | 1.0 |
Kinetics | 6 | 0.0 |
Cefotaxime/pharmacology | 4 | 66.0 |
Cephalosporins/pharmacology | 4 | 50.0 |
Hungary | 2 | 3.0 |
*Penicillin Resistance/genetics | 2 | 66.0 |
Transformation, Bacterial | 5 | 25.0 |
Drug Resistance, Microbial/genetics | 4 | 4.0 |
English Abstract | 6 | 0.0 |
Streptococcus pneumoniae/drug effects/*genetics/isolation & purification | 2 | 100.0 |
Cell Differentiation | 2 | 0.0 |
Rats | 2 | 0.0 |
Carrier Proteins/*metabolism | 5 | 0.0 |
Cell Nucleus/metabolism | 3 | 0.0 |
Hela Cells | 6 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 6 | 0.0 |
Transcription Factors/*metabolism | 4 | 0.0 |
*Transcription, Genetic | 5 | 0.0 |
Bacterial Proteins/*genetics | 3 | 5.0 |
Drug Resistance, Microbial/*genetics | 2 | 10.0 |
Methicillin Resistance/*genetics | 3 | 27.0 |
Epidemiology, Molecular | 3 | 3.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Pneumococcal Infections/*microbiology | 3 | 100.0 |
beta-Lactam Resistance/*genetics | 3 | 100.0 |
Muramoylpentapeptide Carboxypeptidase/*metabolism | 2 | 40.0 |
Muramoylpentapeptide Carboxypeptidase/*analysis | 3 | 100.0 |
*Genes, Bacterial | 2 | 2.0 |
Transcription, Genetic | 6 | 0.0 |
DNA Fingerprinting | 6 | 5.0 |
DNA Primers | 5 | 0.0 |
COS Cells | 3 | 0.0 |
Carrier Proteins/genetics/*metabolism | 3 | 0.0 |
Muramoylpentapeptide Carboxypeptidase/genetics/*metabolism | 2 | 66.0 |
Cefotaxime/*pharmacology | 2 | 100.0 |
DNA Probes | 4 | 0.0 |
Penicillin Resistance/*genetics | 6 | 100.0 |
Ampicillin/pharmacology | 2 | 50.0 |
Drug Resistance, Microbial | 5 | 3.0 |
Gram-Positive Bacterial Infections/microbiology | 2 | 66.0 |
Imipenem/pharmacology | 2 | 33.0 |
Spain/epidemiology | 2 | 1.0 |
Species Specificity | 4 | 0.0 |
DNA, Bacterial/*analysis | 2 | 11.0 |
*Mutation | 2 | 0.0 |
*Chemokines | 6 | 60.0 |
Gene Expression Regulation | 2 | 0.0 |
Trans-Activators/*metabolism | 2 | 0.0 |
Chromatography, Ion Exchange | 2 | 0.0 |
*Promoter Regions (Genetics) | 5 | 0.0 |
Templates, Genetic | 2 | 1.0 |
Transcription Factors/isolation & purification/*metabolism | 2 | 3.0 |
Cells, Cultured | 7 | 0.0 |
Polymerase Chain Reaction/*methods | 2 | 0.0 |
Streptococcus pneumoniae/*drug effects/genetics | 2 | 100.0 |
Chemotaxis, Leukocyte/drug effects | 2 | 2.0 |
Models, Molecular | 2 | 0.0 |
Pneumococcal Infections/epidemiology/*microbiology | 2 | 100.0 |
Penicillins/metabolism | 4 | 80.0 |
DNA, Bacterial/chemistry | 2 | 25.0 |
Pregnancy | 3 | 0.0 |
Chromatography, Affinity | 2 | 0.0 |
Macromolecular Substances | 3 | 0.0 |
Tumor Cells, Cultured | 3 | 0.0 |
*Transcription Factors | 2 | 0.0 |
Blotting, Western | 2 | 0.0 |
Chromatography, Gel | 2 | 0.0 |
Isoelectric Focusing | 3 | 0.0 |
Peptides/chemistry/*metabolism | 2 | 11.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
RNA, Small Nuclear/*genetics | 3 | 10.0 |
TATA-Box Binding Protein | 2 | 0.0 |
Protein Conformation | 2 | 0.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
Spain | 2 | 0.0 |
Streptococcus pneumoniae/*drug effects | 3 | 37.0 |
Anti-Bacterial Agents/*therapeutic use | 2 | 4.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Heparin/metabolism | 2 | 1.0 |
*Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Gene Expression Regulation/drug effects | 2 | 0.0 |
T-Lymphocytes/drug effects/*immunology | 2 | 1.0 |
Enzymes/analysis | 2 | 25.0 |
Blotting, Northern | 2 | 0.0 |
Oxacillin/pharmacology | 2 | 66.0 |
Pancreatic Elastase/metabolism | 2 | 6.0 |
*Peptide Biosynthesis | 2 | 6.0 |
Trypsin/metabolism | 2 | 1.0 |
Cefuroxime/pharmacology/*therapeutic use | 2 | 100.0 |
Interleukin-8 | 2 | 11.0 |
Methicillin/*pharmacology | 2 | 40.0 |
Carrier Proteins/*analysis | 2 | 2.0 |
Blood Platelets/*analysis | 2 | 11.0 |
Immune Sera | 2 | 0.0 |
